|
1
|
Vogelstein B, Fearon ER, Hamilton SR, et
al: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruce WR, Wolever TM and Giacca A:
Mechanisms linking diet and colorectal cancer: the possible role of
insulin resistance. Nutr Cancer. 37:19–26. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hussain SP, Hofseth LJ and Harris CC:
Radical causes of cancer. Nat Rev Cancer. 3:276–285. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mariani F, Sena P, Marzona L, Riccio M,
Fano R, Manni P, et al: Cyclooxygenase-2 and Hypoxia-Inducible
Factor-1alpha protein expression is related to inflammation, and
up-regulated since the early steps of colorectal carcinogenesis.
Cancer Lett. 279:221–229. 2009. View Article : Google Scholar
|
|
6
|
Adegboyega PA, Ololade O, Saada J, Mifflin
R, Di Mari JF and Powell DW: Subepithelial myofibroblasts express
cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res.
10:5870–5879. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hawcroft G, Ko CW and Hull MA:
Prostaglandin E2-EP4 receptor signalling promotes tumorigenic
behaviour of HT-29 human colorectal cancer cells. Oncogene.
26:3006–3019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Tang XM, Half E, Kuo MT and
Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic
susceptibility by inhibiting the cytochrome c-dependent apoptotic
pathway in human colon cancer cells. Cancer Res. 62:6323–6328.
2002.PubMed/NCBI
|
|
9
|
Eberhart CE, Coffey RJ, Radhika A,
Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of
cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas. Gastroenterology. 107:1183–1188. 1994.PubMed/NCBI
|
|
10
|
Levy BD, Clish CB, Schmidt B, Gronert K
and Serhan CN: Lipid mediator class switching during acute
inflammation: signals in resolution. Nat Immunol. 2:612–619. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Charalambous MP, Lightfoot T, Speirs V,
Horgan K and Gooderham NJ: Expression of COX-2, NF-kappaB-p65,
NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human
colorectal tissue. Br J Cancer. 101:106–115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sano H, Kawahito Y, Wilder RL, Hashiramoto
A, Mukai S, Asai K, et al: Expression of cyclooxygenase-1 and −2 in
human colorectal cancer. Cancer Res. 55:3785–3789. 1995.
|
|
13
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygenases in inflammation, cancer and development.
Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang M, Deng CS, Zheng JJ and Xia J:
Curcumin regulated shift from Th1 to Th2 in trinitrobenzene
sulphonic acid-induced chronic colitis. Acta Pharmacol Sin.
27:1071–1077. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamazaki K, Shimizu M, Okuno M,
Matsushima-Nishiwaki R, Kanemura N, Araki H, et al: Synergistic
effects of RXR alpha and PPAR gamma ligands to inhibit growth in
human colon cancer cells - phosphorylated RXR alpha is a critical
target for colon cancer management. Gut. 56:1557–1563. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kitamura S, Miyazaki Y, Shinomura Y, Kondo
S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated
receptor gamma induces growth arrest and differentiation markers of
human colon cancer cells. Jpn J Cancer Res. 90:75–80. 1999.
View Article : Google Scholar
|
|
17
|
Kohno H, Suzuki R, Sugie S and Tanaka T:
Suppression of colitis-related mouse colon carcinogenesis by a
COX-2 inhibitor and PPAR ligands. BMC Cancer. 5:462005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuri M, Sasahira T, Nakai K, Ishimaru S,
Ohmori H and Kuniyasu H: Reversal of expression of
15-lipoxygenase-1 to cyclooxygenase-2 is associated with
development of colonic cancer. Histopathology. 51:520–527. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sarraf P, Mueller E, Jones D, King FJ,
DeAngelo DJ, Partridge B, et al: Differentiation and reversal of
malignant changes in colon cancer through PPARgamma. Nat Med.
4:1046–1052. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tseng YS, Tzeng CC, Huang CY, Chen PH,
Chiu AW, Hsu PY, et al: Aurora-A overexpression associates with
Ha-ras codon-12 mutation and blackfoot disease endemic area in
bladder cancer. Cancer Lett. 241:93–101. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng HL, Trink B, Tzai TS, Liu HS, Chan
SH, Ho CL, Sidransky D and Chow NH: Overexpression of c-met as a
prognostic indicator for transitional cell carcinoma of the urinary
bladder: a comparison with p53 nuclear accumulation. J Clin Oncol.
20:1544–1550. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cutler NS, Graves-Deal R, LaFleur BJ, Gao
Z, Boman BM, Whitehead RH, et al: Stromal production of
prostacyclin confers an antiapoptotic effect to colonic epithelial
cells. Cancer Res. 63:1748–1751. 2003.PubMed/NCBI
|
|
23
|
DuBois RN, Shao J, Tsujii M, Sheng H and
Beauchamp RD: G1 delay in cells overexpressing prostaglandin
endoperoxide synthase-2. Cancer Res. 56:733–737. 1996.PubMed/NCBI
|
|
24
|
Vandoros GP, Konstantinopoulos PA,
Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV,
et al: PPAR-gamma is expressed and NF-kB pathway is activated and
correlates positively with COX-2 expression in stromal
myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin
Oncol. 132:76–84. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Karnes WE Jr, Shattuck-Brandt R, Burgart
LJ, DuBois RN, Tester DJ, Cunningham JM, et al: Reduced COX-2
protein in colorectal cancer with defective mismatch repair. Cancer
Res. 58:5473–5477. 1998.PubMed/NCBI
|
|
26
|
Zuo X, Wu Y, Morris JS, Stimmel JB,
Leesnitzer LM, Fischer SM, Lippman SM and Shureiqi I: Oxidative
metabolism of linoleic acid modulates PPAR-beta/delta suppression
of PPAR-gamma activity. Oncogene. 25:1225–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
DuBois RN, Gupta R, Brockman J, Reddy BS,
Krakow SL and Lazar MA: The nuclear eicosanoid receptor, PPARgamma,
is aberrantly expressed in colonic cancers. Carcinogenesis.
19:49–53. 1998. View Article : Google Scholar : PubMed/NCBI
|
